
Europe’s regulator upholds AstraZeneca's COVID-19 vaccine amid blood clot reports
Fox News
A safety committee for Europe’s regulator confirmed Wednesday that the benefits for AstraZeneca’s COVID-19 vaccine continue to outweigh risks of side effects, after a review of rare and unusual blood clotting among vaccinated adults.
"Based on the current available evidence, specific risk factors such as age, gender, or previous medical history of clotting disorders have not been able to be confirmed as the rare events are seen in all ages and in men and women," said Emer Cooke, executive director of the European Medicines Agency (EMA). The committee reviewed 62 cases of cerebral venous sinus thrombosis (CVST) and 24 cases of splanchnic vein thrombosis (SVT) through the EU drug safety database. As of March 22, 18 of the cases were fatal, and the cases came mainly from reporting systems in the European Economic Area and the U.K., Straus said. As of April 4, the EU drug safety database received 169 total cases of CVST and 53 cases of SVT amid a backdrop of 34 million vaccinated individuals.More Related News